Sensus Healthcare (SRTS) to Release Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS – Get Rating) will post its quarterly earnings results after the market closes on Thursday, May 5th. Analysts expect Sensus Healthcare to post earnings of $0.06 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Sensus Healthcare (NASDAQ:SRTS – Get Rating) last posted its quarterly earnings data on Thursday, February 10th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.18. The company had revenue of $13.03 million during the quarter, compared to analyst estimates of $11.01 million. Sensus Healthcare had a return on equity of 18.88% and a net margin of 15.23%. During the same quarter last year, the company earned $0.06 earnings per share. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ:SRTS opened at $7.11 on Thursday. The firm has a market capitalization of $118.43 million, a price-to-earnings ratio of 29.63 and a beta of 0.30. Sensus Healthcare has a 52-week low of $3.08 and a 52-week high of $11.96. The stock has a fifty day moving average of $9.79 and a 200 day moving average of $7.76.

In other news, COO Nicolas Soro sold 10,000 shares of Sensus Healthcare stock in a transaction dated Wednesday, March 9th. The stock was sold at an average price of $10.20, for a total value of $102,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Javier Rampolla sold 9,000 shares of Sensus Healthcare stock in a transaction dated Friday, March 4th. The stock was sold at an average price of $9.42, for a total value of $84,780.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,056 shares of company stock worth $1,151,818. Company insiders own 24.30% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRTS. Morgan Stanley increased its holdings in shares of Sensus Healthcare by 340.4% in the first quarter. Morgan Stanley now owns 44,894 shares of the company’s stock worth $172,000 after buying an additional 34,699 shares during the period. Dimensional Fund Advisors LP increased its holdings in Sensus Healthcare by 47.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 68,298 shares of the company’s stock valued at $493,000 after purchasing an additional 22,015 shares during the period. Renaissance Technologies LLC increased its holdings in Sensus Healthcare by 634.9% during the 4th quarter. Renaissance Technologies LLC now owns 161,934 shares of the company’s stock valued at $1,169,000 after purchasing an additional 139,900 shares during the period. Geode Capital Management LLC increased its holdings in Sensus Healthcare by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 90,964 shares of the company’s stock valued at $656,000 after purchasing an additional 21,632 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new position in Sensus Healthcare during the 4th quarter valued at about $141,000. Hedge funds and other institutional investors own 14.64% of the company’s stock.

SRTS has been the topic of a number of research reports. TheStreet upgraded Sensus Healthcare from a “c” rating to a “b-” rating in a research report on Friday, February 11th. Maxim Group initiated coverage on Sensus Healthcare in a research report on Friday, February 11th. They set a “buy” rating and a $12.00 price target on the stock. Finally, HC Wainwright raised their price target on Sensus Healthcare from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Thursday, March 3rd.

About Sensus Healthcare (Get Rating)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Further Reading